Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
Authors: Kreimer AR,  Struyf F,  Del Rosario-Raymundo MR,  Hildesheim A,  Skinner SR,  Wacholder S,  Garland SM,  Herrero R,  David MP,  Wheeler CM,  Costa Rica Vaccine Trial Study Group Authors,  González P,  Jiménez S,  Lowy DR,  Pinto LA,  Porras C,  Rodriguez AC,  Safaeian M,  Schiffman M,  Schiller JT,  Schussler J,  Sherman ME,  PATRICIA Study Group Authors,  Bosch FX,  Castellsague X,  Chatterjee A,  Chow SN,  Descamps D,  Diaz-Mitoma F,  Dubin G,  Germar MJ,  Harper DM,  Lewis DJ,  Limson G,  Naud P,  Peters K,  Poppe WA,  Ramjattan B,  Romanowski B,  Salmeron J,  Schwarz TF,  Teixeira JC,  Tjalma WA,  HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators,  GSK Vaccines Clinical Study Support Group
Journal: Lancet Oncol
Date: 2015 Jul
Branches: BB, CGB, IIB, MEB, REB
PubMed ID: 26071347
PMC ID: PMC4498478
Abstract: BACKGROUND: There is some evidence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dose regimen. The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV types, by number of doses received. METHODS: Summary data from the Costa Rica Vaccine Trial (CVT; NCT00128661) and ~the PATRICIA trial (NCT001226810), two phase 3, double-blind, randomised controlled clinical trials of the HPV-16/18 AS04-adjuvanted vaccine in young women, were combined in a post-hoc analysis (GlaxoSmithKline [GSK] e-track number 202142) to investigate the efficacy of fewer than three doses of the HPV-16/18 vaccine after 4 years of follow-up. Women were randomly assigned to receive three doses of the HPV-16/18 vaccine or to a control vaccine; yet, some received fewer doses. After exclusion of women with less than 12 months of follow-up or those who were HPV-16/18 DNA-positive at enrolment (for the HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident HPV infections after three, two, and one dose(s). The primary study endpoint was one-time detection of first incident HPV-16/18 infections accumulated during the follow-up phase. FINDINGS: We assessed vaccine efficacy against incident HPV-16/18 infection in the modified total vaccinated cohort (22 327 received three doses, 1185 two doses, 543 one dose). Vaccine efficacy against incident HPV-16/18 infections for three doses was 77·0% (95% CI 74·7-79·1), two doses was 76·0% (62·0-85·3), and one dose was 85·7% (70·7-93·7). Vaccine efficacy against incident HPV-31/33/45 infections for three doses was 59·7% (56·0-63·0), two doses was 37·7% (12·4-55·9), and one dose was 36·6% (-5·4 to 62·2). Vaccine efficacy against incident HPV-16/18 infection for two-dose women who received their second dose at 1 month was 75·3% (54·2-87·5) and 82·6% (42·3-96·1) for those who received the second dose at 6 months (CVT data only). Vaccine efficacy against HPV-31/33/45 for two-dose women who received their second dose at 6 months (68·1%, 27·0-87·0; CVT data only), but not those receiving it at one month (10·1%, -42·0 to 43·3), was similar to the three-dose group. INTERPRETATION: 4 years after vaccination of women aged 15-25 years, one and two doses of the HPV-16/18 vaccine seem to protect against cervical HPV-16/18 infections, similar to the protection provided by the three-dose schedule. Two doses separated by 6 months additionally provided some cross-protection. These data argue for a direct assessment of one-dose efficacy of the HPV-16/18 vaccine. FUNDING: US National Cancer Institute, National Institutes of Health Office of Research on Women's Health, and Ministry of Health of Costa Rica (CVT); GlaxoSmithKline Biologicals SA (PATRICIA).